Ownership and insider activity for Lexicon Pharmaceuticals, Inc. (LXRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain...
Price
| Price | $2.02 |
| Market Cap | $897M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-03 | Swain Judith L | M-Exempt | 89,312 | |
| 2026-06-03 | Swain Judith L | M-Exempt | 89,312 | |
| 2026-06-03 | Sullivan Diane E. | M-Exempt | 89,312 | |
| 2026-06-03 | Sullivan Diane E. | M-Exempt | 89,312 | |
| 2026-06-03 | SOBECKI CHRISTOPHER J | M-Exempt | 89,312 | |
| 2026-06-03 | SOBECKI CHRISTOPHER J | M-Exempt | 89,312 | |
| 2026-06-03 | Cheung Ivan | M-Exempt | 89,312 | |
| 2026-06-03 | Cheung Ivan | M-Exempt | 89,312 | |
| 2026-06-03 | BARKER SAM L | M-Exempt | 89,312 | |
| 2026-06-03 | BARKER SAM L | M-Exempt | 89,312 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $346.5M | $310.8M | $160.1M | $36.1M | $126.3M | $64.1M | $46.3M | $22.5M | $66.7M | $34.3M |
| Short-term Investments | 0 | 0 | 0 | $235.5M | $26.0M | $22.7M | $92.0M | $147.6M | $171.3M | $61.9M |
| Receivables | $7.5M | $4.8M | $5.9M | $56.5M | $395000 | $14000 | $28000 | $1.0M | $3.5M | $2.4M |
| Inventory | 0 | $1.9M | $4.7M | $4.2M | 0 | 0 | 0 | $381000 | $231000 | $281000 |
| Total Current Assets | $357.9M | $322.0M | $173.3M | $337.8M | $157.7M | $88.9M | $140.9M | $176.5M | $246.2M | $101.9M |
| Property, Plant & Equipment | $19.4M | $17.7M | $15.9M | $14.0M | $295000 | $3.4M | $8.5M | $7.5M | $7.3M | $9.2M |
| Goodwill | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M |
| Intangible Assets | $53.4M | $51.9M | $50.1M | $19.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $475.6M | $436.5M | $284.1M | $417.7M | $203.8M | $136.9M | $194.3M | $229.4M | $298.4M | $185.0M |
| Accounts Payable | $52.9M | $38.8M | $12.1M | $12.2M | $5.5M | $9.2M | $10.4M | $14.4M | $14.8M | $3.1M |
| Short-term Debt | $16.3M | $14.1M | $1.1M | $11.0M | $11.6M | 0 | 0 | 0 | 0 | $6.2M |
| Total Current Liabilities | $164.6M | $124.1M | $36.8M | $65.3M | $46.8M | $22.1M | $23.2M | $31.5M | $45.2M | $20.9M |
| Long-term Debt | $85.2M | $231.6M | $243.9M | $234.2M | 0 | 0 | $48.6M | $99.5M | $100.3M | $49.4M |
| Total Liabilities | $318.2M | $384.4M | $310.5M | $300.6M | $47.4M | $23.3M | $77.2M | $136.3M | $152.5M | $77.4M |
| Retained Earnings | -$1.25B | -$1.38B | -$1.47B | -$1.34B | -$1.40B | -$1.49B | -$1.59B | -$1.77B | -$1.97B | -$2.02B |
| Total Equity | $157.4M | $52.1M | -$1.47B | $117.1M | $156.4M | $113.6M | $117.1M | $93.1M | $145.9M | $107.5M |
| Total Debt | $101.4M | $245.7M | $245.0M | $246.8M | $12.8M | $2.3M | $55.3M | $106.1M | $108.4M | $62.2M |
| Net Debt | -$245.1M | -$65.1M | $85.0M | -$24.8M | -$139.5M | -$84.5M | -$83.1M | -$64.0M | -$129.6M | -$34.0M |
| Working Capital | $193.2M | $197.9M | $136.6M | $272.4M | $110.9M | $66.8M | $117.7M | $145.0M | $200.9M | $81.0M |
Financial Health
| Debt / Equity | 0.34 |
| Current Ratio | 13.37 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -12.11 |
Profitability
| Return on Equity | -40.40% |
| Return on Invested Capital | -23.00% |
| Return on Assets | -24.44% |
| Gross Margin | 98.85% |
| Operating Margin | -131.43% |
| Net Margin | -147.38% |
Related companies: ADCT · BCYC · CMPX · FDMT · FULC · GOSS · NMRA
Explore sector: Healthcare · Biotechnology
More sections of LXRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks